Fundraising FoxArch Therapeutics
Wellesley, US · Founded 2009 · Nevada corporation
Find your way into Arch Therapeutics
247 people in our graph share verified history with the Arch Therapeutics team — schools, employers, funds. One of them is your warm intro.
Mike Salguerounlockedknows Terrence Norchi · together at Newton-Wellesley Hospital (overlapped)
knows the team · via Cohera Medical, Inc
×2knows the team · via Helicos BioSciences
×5knows the team · via Museum of Science
×3knows the team · via Putnam Investments
Arch Therapeutics develops the AC5 Advanced Wound System, a wound care product available in the USA for both government and non-government purchasers. The company operates in the medical device sector focused on wound management.
Founders & leadership
Arch Therapeutics was founded in 2009 by Terrence Norchi and Norchi Terrence.
TN
Terrence NorchiCo-founderTerrence Norchi is a physician and CEO of Arch Therapeutics, which he co-founded based on MIT-licensed intellectual property to develop self-assembling peptide technology for wound care; he previously managed a $4 billion healthcare mutual fund.
NT
Norchi TerrenceCo-founderNorchi Terrence is a physician and co-founder of Arch Therapeutics, which developed the AC5 Advanced Wound System and self-assembling peptide technology for wound and surgical care. He previously served as a portfolio manager for a $4 billion healthcare mutual fund.
WC
William CotterChief Operating Officer (COO) - July 2013 to July 20152012–2015He has held senior leadership roles in product development, operations, quality and regulatory affairs, and strategic partnerships across the medical devices, diagnostics, and biologics sectors.
RD
Richard DavisExecutive
AB
Alan BarberExecutive
Board
AD
Avtar DhillonBoard director
AR
Arthur RosenthalBoard director
Reported raises · per SEC filings
Form D private placements$18.7M disclosed across 6 rounds · 2014–2022
▶$4.2MraisedJul 2022 · 16 investors · BiotechnologyRule 506(b)
▶$4.2MraisedJul 2022 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Guy FishDirector
- Laurence HicksDirector
- Daniel M. YrigoyenExecutive Officer
- Terrence W. NorchiExecutive Officer, Director
- Punit DhillonDirector
- Michael S. AbramsExecutive Officer
- Offering amount
- $4.2M
- Amount sold
- $4.2M
- Sales commissions
- $240K
- Placement agents
- Maxim Group LLP
- First sale
- Jul 2022
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$6.9MraisedFeb 2021 · 9 investors · BiotechnologyRule 506(b)
▶$6.9MraisedFeb 2021 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Terrence W. NorchiExecutive Officer, Director
- Richard E. DavisExecutive Officer
- James R. SulatDirector
- Punit DhillonDirector
- Offering amount
- $7.5M
- Amount sold
- $6.9M
- Sales commissions
- $492.8K
- Placement agents
- H.C. Wainwright & Co.
- First sale
- Feb 2021
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$550KraisedJun 2020 · 4 investors · BiotechnologyRule 506(b)
▶$550KraisedJun 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Terrence W. NorchiExecutive Officer, Director
- Richard E. DavisExecutive Officer
- Punit DhillonDirector
- James R. SulatDirector
- Offering amount
- $2M
- Amount sold
- $550K
- First sale
- Jun 2020
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3.4MraisedJun 2016 · 18 investors · BiotechnologyRule 506(b)
▶$3.4MraisedJun 2016 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Terrence W. NorchiExecutive Officer, Director
- James R. SulatDirector
- Avtar DhillonDirector
- Richard E. DavisExecutive Officer
- Offering amount
- $3.5M
- Amount sold
- $3.4M
- Sales commissions
- $171K
- Placement agents
- MAXIM GROUP LLC
- First sale
- May 2016
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$750KraisedMar 2015 · 3 investors · BiotechnologyRule 506(b)
▶$750KraisedMar 2015 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William CotterExecutive Officer
- Terrence NorchiExecutive Officer, Director
- Richard DavisExecutive Officer
- Avtar DhillonDirector
- Arthur RosenthalDirector
- Offering amount
- $750K
- Amount sold
- $750K
- First sale
- Mar 2015
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$2.9MraisedFeb 2014 · 9 investors · BiotechnologyRule 506(b)
▶$2.9MraisedFeb 2014 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Avtar DhillonDirector
- William CotterExecutive Officer
- Norchi TerrenceExecutive Officer, Director
- Arthur RosenthalDirector
- Alan BarberExecutive Officer
- Offering amount
- $2.9M
- Amount sold
- $2.9M
- First sale
- Feb 2014
- Incorporated
- Corporation, Nevada, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Arch Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Arch Therapeutics do?
- Arch Therapeutics develops the AC5 Advanced Wound System, a wound care product available in the USA for both government and non-government purchasers. The company operates in the medical device sector focused on wound management.
- Who founded Arch Therapeutics?
- Arch Therapeutics was founded by Terrence Norchi, Norchi Terrence in 2009.
- How much funding has Arch Therapeutics raised?
- Arch Therapeutics has disclosed $18.7M raised across 6 rounds.
- Where is Arch Therapeutics headquartered?
- Arch Therapeutics is headquartered in Wellesley, US.